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inter-observer variability compared to post-operative 
radiosurgery. 
Methods and Materials: We identified 10 consecutive patients, 
with solitary brain metastasis, treated with post-operative cavity 
radiosurgery. Pre- and post-operative axial T1 contrast MRI were 
co-registered with the planning CT scans. Three radiation 
oncologists independently contoured the target volumes on the 
pre- and post-operative imaging and CyberKnife treatment plans 
were generated. The following parameters were evaluated in the 
two plans: Mean target volume (cc), 50% isodose volume(cc), 
Inter-observer variability (Jaccard Index JI) and Conformity Index 
(CI). Results were analyzed with STATA version 14. 
Results: Radiosurgery doses ranged from 18 Gy in 1 to 30 Gy in 5 
fractions depending on the location and volume (Median 24 Gy in 
3 fractions). There was no significant difference in the mean 
target volume, nor 50% isodose volume, between pre- and post-
operative strategies. (17.6 +- SD 12.3 versus 19.4+-15 cc, p = 
0.80; 61.7 +-37.7 versus 77.7 +- 69.0 cc, p = 0.65). There was 
significantly less inter-observer variability and improved 
conformity in the pre-operative group (Mean JI 0.84+-0.04 versus 
0.70+-0.13, p = 0.005; Mean CI 1.32 +- 0.09 versus 1.45 +-0.14, p 
= 0.01). Planned subgroup analysis did not reveal any significant 
difference (between pre- versus post-op) in the mean volume of 
cystic versus non-cystic metastasis. Deep lesions (> 2.5 cm from 
dura) had a larger post-operative target volume (25.8+-17.3 
versus 12.3+-9.3 cc, p = 0.06) compared to superficial lesions. 
Conclusions: Pre-operative radiosurgery has less inter-observer 
variability and improved plan conformity. However, there was no 
difference in mean target volume between the pre- versus post-
operative radiation. Contouring guidelines, and peer review, may 
help to reduce inter-observer variability for cavity radiosurgery.  
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Purpose: In the setting of limited metastatic burden of disease, 
stereotactic body radiotherapy (SBRT) has been shown to achieve 
high local control rates. It has been hypothesized that SBRT may 
translate to better quality of life by delaying the need for 
systemic chemotherapy and possibly increased survival. There is 
limited published literature on the efficacy of SBRT in limited 
nodal metastases. The primary objective is to report the clinical 
outcome of SBRT in a series of patients with either solitary or 
oligometastases from various tumours to lymph nodes. 
Methods and Materials: A retrospective study of patients treated 
on a provincial protocol with SBRT to metastatic lymph nodes 
(March 2010 and June 2015) was conducted. Primary endpoint 
was local control (LC) and chemotherapy free survival following 
SBRT. Secondary endpoints included toxicities, progression-free 
survival (PFS), and overall survival (OS). 
Results: Eighteen patients underwent SBRT to a metastatic 
lymph node with a mean age of 61.8 years (range: 20-84 years) 
and a median follow up of 22 months. There were four (22%) 
liver, seven (39%) colorectal, four (22%) pancreatic, one (6%) 
esophageal, one (6%) gallbladder and one (6%) lung primary. 
Eleven (61%) patients had lymph node metastases as part of their 
initial presentation of metastatic disease. Seven patients (39%) 
had systemic therapy prior to SBRT, with the majority of patients 
(71%) receiving two lines of chemotherapy. Eight patients had 
solitary metastatic disease at the time of SBRT, with all patients 
having four or fewer total sites of metastases. Average size of 
the lymph node metastases was 2.3 cm (range: 0.8-6.2 cm). RT 
doses were 31 to 60 Gy in four to ten fractions, with 44% of 
patients receiving 35 Gy in 5 fractions. At one year, LC was 93% 
and chemotherapy-free survival from the time of SBRT was 58%. 
PFS at one and two years were 42% and 18% respectively. One 
and two year OS were 92% and 84%. There were no Grade 3 or 
higher toxicities reported. On univariate analysis, absence of 
prior chemotherapy and non-colorectal primary approached 
significance for improved local control (both p = 0.052) while 
solitary metastases was associated with improved PFS (p = 0.029) 
and trended to improved chemotherapy-free survival (p = 0.066). 
Conclusions: In this single institution study, SBRT to 
oligometastatic lymph nodes provides high local control and a 
moderate chemotherapy-free interval with acceptable 
toxicities. Progression of disease remains prominent in these 
patients. Larger cohort studies are required to better identify a 
subset of patients with oligometastatic nodal disease who 
benefit the most from SBRT. 
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Purpose: The management of retroperitoneal sarcomas (RPS) 
may include pre-operative radiotherapy (RT) and surgery. As RPS 
often require multi-visceral resection, combined treatment of 
RPS can be associated with substantial toxicity as radiation 
sensitive organs may be affected by pre-op RT. We aimed to 
examine how these treatments related toxicities affect patient 
quality of life (QOL).  
Methods and Materials: In a cross-sectional study, 25 primary 
RPS patients treated with pre-operative IMRT from 2004-2012 
were recruited and assessed for QOL (EORTC QLQ-C30) and to 
determine RT and surgery related toxicities (CTCAE V.4). 
Baseline and prospective QOL was available for 11 patients. In 
the other 14 patients cross-sectional data alone were obtained 
at different time points during their follow up (four weeks, six 
months, one year, three years, five years and 10 years post-
IMRT). Unless stated otherwise, all scores refer to the global 
domain. 
Results: Ten female and 15 male patients with a median age of 
56 (38-80) were treated with IMRT to a median dose of 50.4 Gy 
(41.4-50.4). The median maximum dimension was 13.4 cm (5.7-
28) and the majority (17/25) were liposarcomas. The median 
time from completion of RT to RPS surgery was 9.4 weeks (5-
17.4). Of the 11 patients who completed baseline QOL 
assessments, their compliance at four weeks, six months, one 
year and three years post-RT were 80%, 100%, 90%, and 100%. 
Mean pre-RT QOL was 48.5 (standard deviation (SD) 19.3). At four 
weeks post-RT, mean QOL was 57.5 (SD: 23.7) however, the 
mean diarrhea symptom scale increased from baseline (85 versus 
18.1, p < 0.001). Correspondingly, 54% of patients had 
gastrointestinal toxicities (32% G1, 56% G2 and 8% G3) by the end 
of RT. Regression slope analysis suggested that QOL significantly 
(p = 0.002) improved over the first three years. The number of 
toxicities was significantly (p = 0.002) associated with QOL over 
time. Clinically important improvement (> 10 points) from 
baseline was observed at one year (68.6, SD: 18.4). At three 
years post-RT, 88% of patients had chronic RT and/or surgery 
related toxicities of which 30% were Grade 3 toxicities. RPS 
patients who survived at least three years had significantly 
better QOL (mean: 67.2, p = 0.007 Mann-Whitney Test) relative 
to the full group at diagnosis. QOL changed little (mean: 0.31 
point/month; SD: 0.36) after three years (n = 10). RT dose, 
tumour size, patient age and gender were not associated with 
three year QOL scores.  
Conclusions: Treatment toxicities seem to contribute to QOL 
recovery during the first three years. The number of toxicities a 
patient had was significantly associated with QOL. Despite 
patients having on average 2.5 treatment-related chronic 
toxicities, QOL at three years was better than at diagnosis. 
 
 
 
 
 
